Scalable non-viral gene delivery for a common muscular dystrophy
Official title: Scalable Non-viral Gene Delivery for Neuromuscular Diseases
Funded at Kinea Bio, INC. · NIH-11525063 · Data updated 2026-11-12
A patient-focused project tests a non-viral therapy to reduce harmful DMPK RNA in muscle because this could lessen symptoms of myotonic dystrophy type 1.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kinea Bio, INC. NIH-funded |
| Lab location | 1 site (Mukilteo, UNITED STATES) |
| Project start | September 23, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,021,458 |
| NIH project number | 4R44AR084978-02 |
| Project ID | NIH-11525063 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with myotonic dystrophy type 1 or patients providing patient-derived cells (iPSCs) for research.
✕Less likely to help
People without DM1 or those whose disease biology does not respond to the proposed RNA-based approach may not benefit.
What this research studies
This project will screen 15 different RNAi-based nanovesicle treatments in human patient-derived stem cells to find a safe, effective way to lower toxic DMPK mRNA. The best-performing constructs will be studied further in animal models to understand how well they work and how they move through the body. In Phase 2, the team aims to generate data that could support regulatory approval for a potential product, using non-viral delivery to avoid some risks of viral therapies. If successful, this approach could lead to a more affordable and safer option for people living with DM1.
Why it matters
Potential benefit: If successful, this non-viral therapy could reduce DM1 symptoms and improve quality of life by lowering the toxic DMPK RNA in muscle and related tissues.
How similar studies have gone: Previous similar RNA-based, non-viral approaches have shown promise in cell models, with ongoing exploration in animals; this study seeks to translate that to human-derived cells and DM1 models.
Where this research is happening
-
Kinea Bio, INC.
Mukilteo, United States Active
Researchers
- Principal investigator: Childers, Martin K — Kinea Bio, INC.
- Study coordinator: Childers, Martin K
Related research
Other NIH-funded projects on the same topics.
-
Human iPSC NMJ models to study neuromuscular diseases
Scientists are building patient-friendly lab models using stem cells from humans to study how neuromuscular diseases like ALS affect the connection between nerves and muscles.
-
Antibody therapy to protect muscles in Duchenne and related diseases
A small drug company is developing antibodies that target a key protein (LTBP4) to calm harmful signals in muscles affected by Duchenne muscular dystrophy and similar conditions, with a plan to test safety and dosing in people soon.
-
Human nerve–muscle junctions grown from patient stem cells to model ALS and related neuromuscular diseases
They are growing human nerve-to-muscle connections from patient stem cells to help develop better treatments for people with ALS and similar neuromuscular conditions.
-
Creating a treatment for neuromuscular diseases using anti-LTBP4.
This study is looking at a new treatment that targets a protein called LTBP4 to help improve muscle function and slow down Duchenne Muscular Dystrophy (DMD), so that patients can feel better and do more in their daily lives.
-
Using human stem cells to study communication between nerves and muscles in neuromuscular diseases.
This study is exploring how special stem cells can help us create models of the connections between nerves and muscles, which are important for movement, to better understand diseases like ALS and find new ways to treat them.
-
Wearable monitoring of walking and arm movement in adults with neuromuscular or metabolic movement disorders
This project uses a wrist/ankle wearable to continuously monitor walking and upper-limb movement in ambulant adults with neuromuscular diseases or obesity to see if digital measures like stride speed track real-life motor function.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.